
Traversing the Path from Bench to Cancer Biomarker Validation
Recombinant antibodies and rigorous validation standards are advancing cancer biomarker research, bridging the gap between early discovery and clinical translation.


The Importance of Antibody Validation
Antibodies are a core reagent for many cancer biomarker assays, including IHC and enzyme-linked immunosorbent assays (ELISAs), and recombinant antibodies are another key tool for improving validation.